References
- Schlech I IIW, Ward JI, Band JD, Hightower A, Fraser DW, Broom CV. Bacterial meningitis in the United States, 1978 through 1981. JAMA 1985; 253: 1749–1754
- Trollfors B, Claesson BA, Strangert K, Taranger J. Haemophilus influenzae meningitis in Sweden 1981–1983. Arch Dis Child 1987; 62: 1220–1223
- Gilbert GL, Clements DA, Broughton SJ. Haemophilus influenzae type b infections in Victoria. Australia, 1985–1987. Pediatr Infect Dis J 1990; 9: 252–257
- Spanjaard L, Bol P, Ekker W, Zanen HC. The incidence of bacterial meningitis in the Netherlands – a comparison of three registration systems, 1977–1982. J Infect 1985; 11: 259–268
- Takala AK, Eskola J, Peltola H, Mäkelä PH. Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 1989; 8: 297–302
- Peltola H, Kilpi T, Antilla M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340: 592–594
- CDC. Progress toward elimination of Haemophilus influenzae type b disease among infants and children – United States. 1987–1993. MMWR 1994; 43: 144–148
- ACIP. Pneumococcal polysaccharide vaccine. MMWR 1989; 38: 64–76
- National Central Bureau of Statistics. Official statistics of Sweden. Population part 3. National Bureau of Statistics, Stockholm 1986–1989
- Trollfors B. Cost-benefit analysis of general vaccination against Haemophilus influenzae type b in Sweden. Scand J Infect Dis 1994; 26: 611–614
- Reinert P, Liwartowski A, Dabenat H, Guyot C, Boucher J, Carrere C. Epidemiology of Haemophilus influenzae type b disease in France. Vaccine 1993; 11(Suppl. 1)S38–S42
- Claesson B, Trollfors B, Jodal U, Rosenhall U. Incidence and prognosis of Haemophilus influenzae meningitis in children in a Swedish region. Pediatr Infect Dis J 1984; 3: 35–39
- Burman LÅ, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis 1985; 7: 133–142
- Bryan JP, Rodriques de Silva H, Tavares A, Rocha H, Scheld WM. Etiology and mortality of bacterial meningitis in northeastern Brazil. Rev Infect Dis 1990; 12: 128–135
- Cadoz M, Denis F, Diop Mar I. Etude épidémiologique des cas de méningites purulentes hospitalisés à Dakar pendant la décennie 1970–1979. Bull WHD 1981; 59: 575–584
- Fortnum HM, Davis AC. Epidemiology of bacterial meningitis. Arch Dis Child 1993; 68: 763–767
- Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV. Bacterial meningitis study group. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. J Infect Dis 1990; 162: 1316–1323
- Hook I IIEW, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983; 249: 1055–1057
- Mufson MA, Kruss DM, Wasil RE, Metzger WI. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch Intern Med 1974; 134: 505–510
- Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS, Jr., Swartz MN. Acute bacterial meningitis in adults: a review of 493 episodes. N. Engl J Med 1993; 328: 21–28
- Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983; 148: 131–137
- Leinonen M, Säkkinen A, Kalliokoski R, Luotenen J, Timonen M, Mäkelä PH. Antibody response to 14 valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis J 1986; 5: 39–44
- Robbins JB, Austrian R, Lee C-J, Rastogi SC, Schiffman G, Henrichsen J, Mäkelä PH, Broome CV, Facklam RR, Tiesjema RH, Parke JC, Jr. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148: 1135–1159
- Jetté LP, Flamothe F. and the pneumococcus study group. Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility and clinical characteristics. J Clin Microbiol 1989; 27: 1–5
- Berg S, Trollfors B, Alestig K, Jodal U. Incidence, serogroups and case-fatality rate of invasive meningococcal infections in a Swedish region 1975–1989. Scand J Infect Dis 1992; 24: 333–338
- Salwén KM, Vikerfors T, Olcén P. Increased incidence of childhood bacterial meningitis. A 25-year study in a defined population in Sweden. Scand J Infect Dis 1987; 19: 1–11
- Peltola H. Meningococcal disease: still with us. Rev Infect Dis 1983; 5: 71–91
- Samuelsson S, Gustavsen S, Rønne T. Epidemiology of meningococcal disease in Denmark 1980–1988. Scand J Infect Dis 1991; 23: 723–730
- Lystad A, Aasen S. The epidemiology of meningococcal disease in Norway 1975–1991. NIPH Ann 1991; 14: 57–66
- Valmari P, Kataja M, Peltola H. Invasive Haemophilas influenzae and meningococcal infections in Finland. Scand J Infect Dis 1987; 19: 19–27
- Peltola H, Jónsdóttir K, Lystad A, Sievers CJ, Kallings I. Meningococcal disease in Scandinavia. Br Med J 1982; 284: 1618–1621
- Bjune G, Høiby EA, Grønnesby JK, Arnesen Ø, Fredriksen JH, Halstensen A, Holten E, Lindbak A-K, Nøkleby H, Rosenqvist E, Solberg LK, Closs O, Eng J, Frøholm LO, Lystad A, Bakketeig LS, Hareide B. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338: 1993–1996
- Sierra G VG, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casaneuva GV, Rico CO, Rodriguez CR, Terry MH. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14: 195–207
- Cassio de Moares J, Perkins BA, Camargo M CC, Hidalgo N TR, Barbosa HA, Sacchi CT, Gral I ML, Gattas VL, Vasconcelos H de G, Plikaytis BD, Wenger JD, Broome CV. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340: 1074–1078
- Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, Jones EE, Phillips C, Tiendrebeogo H, Yada A. Age-specific difference in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 114–118
- Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977; 60: 673–680
- Ceesay SJ, Allen SJ, Menon A, Todd JE, Cham K, Carlone GM, Turner SH, Gheesling LL, DeWitt W, Plikaytis BD, Greenwood B. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1991; 167: 1212–1216